STOCK TITAN

Coherus Oncology (CHRS) director receives RSU and stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Coherus Oncology director Charles W. Newton reported equity compensation grants. He received 30,000 shares of Common Stock in the form of restricted stock units, with one share delivered for each unit upon vesting. The RSUs vest 100% on the one year anniversary of June 3, 2026, contingent on his continued service.

He was also granted stock options for 60,000 shares of Common Stock at an exercise price of $1.45 per share, expiring on June 5, 2036. These options vest and become exercisable in full on June 3, 2027, also subject to his continued service. After these awards, he holds 30,000 shares of Common Stock and 60,000 options directly.

Positive

  • None.

Negative

  • None.
Insider Newton Charles W.
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 60,000 $0.00 --
Grant/Award Common Stock 30,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 60,000 shares (Direct, null); Common Stock — 30,000 shares (Direct, null)
Footnotes (1)
  1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.
RSU grant 30,000 shares Restricted stock units tied to Common Stock
Option grant 60,000 options Stock Option (Right to Buy) on Common Stock
Option exercise price $1.45 per share Conversion or exercise price for 60,000 options
Option expiration June 5, 2036 Expiration date of stock options
RSU vesting date One year anniversary of June 3, 2026 RSUs vest 100% on this date with continued service
Option vesting date June 3, 2027 Options vest and become exercisable in full
Shares held after grant 30,000 shares Common Stock held directly following RSU award
Options held after grant 60,000 options Stock options held directly following award
restricted stock units ("RSUs") financial
"Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with underlying security title Common Stock and an exercise price of 1.4500."
exercise price financial
"conversion_or_exercise_price of 1.4500 per share for the stock options."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to continued service."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"The stock options have an expiration_date of June 5, 2036."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Newton Charles W.

(Last)(First)(Middle)
C/O COHERUS ONCOLOGY, INC.
333 TWIN DOLPHIN DRIVE, SUITE 600

(Street)
REDWOOD CITY CALIFORNIA 94065

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Coherus Oncology, Inc. [ CHRS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/05/2026A30,000(1)A$030,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.4506/05/2026A60,000 (2)06/05/2036Common Stock60,000$060,000D
Explanation of Responses:
1. Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
2. The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.
/s/ Bryan McMichael, as Attorney in Fact for Charles W. Newton06/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Charles W. Newton acquire in the latest Coherus (CHRS) Form 4?

Charles W. Newton received equity compensation, not open-market trades. He was granted 30,000 restricted stock units tied to Common Stock and stock options for 60,000 shares, all held directly, reflecting a standard board-level compensation structure at Coherus Oncology.

What are the terms of the 30,000 RSUs reported for Coherus (CHRS)?

The 30,000 RSUs entitle Newton to one share of Coherus Common Stock per unit upon vesting. According to the disclosure, 100% of these RSUs vest on the one year anniversary of June 3, 2026, conditioned on his continued service with the company.

What stock options did Charles W. Newton receive from Coherus (CHRS)?

Newton received stock options covering 60,000 shares of Coherus Common Stock at an exercise price of $1.45 per share. These options vest and become fully exercisable on June 3, 2027, and carry an expiration date of June 5, 2036, subject to continued service.

How many Coherus (CHRS) shares and options does Newton hold after this filing?

Following these grants, Newton directly holds 30,000 shares of Coherus Common Stock and 60,000 stock options. The share holdings reflect the RSU award, while the options provide potential future ownership if exercised at the stated $1.45 strike price.

Are the Coherus (CHRS) RSU and option grants tied to service conditions?

Yes, both awards are service-based. The RSUs vest in full on the one year anniversary of June 3, 2026, and the options vest on June 3, 2027. In each case, vesting requires Newton’s continued service relationship with Coherus Oncology through the respective vesting date.